SCHEMBL22076995

SCHEMBL22076995

NC(=O)c1ccc(-n2c3ccc(-n4ccnc4)cc3c3ccc(CCC(=O)O)cc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 4/20 0.47
ADH5 P11766 4/20 0.47
CYP2C19 P33261 1/20 0.47
HAT1 O14929 1/20 0.44
EP300 Q09472 1/20 0.44
PLA2G10 O15496 2/20 0.38
PLA2G4A P47712 2/20 0.38
CYP3A4 P08684 1/20 0.37
BAZ2B Q9UIF8 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
CYP4Z1 Q86W10 1/20 0.37
MAPT P10636 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
SIRT3 Q9NTG7 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22078068 0.89 TBXAS1 (0.50) TBXAS1ADH5CYP2C19HAT1EP300
SCHEMBL22077233 0.89 ADH5 (0.61) TBXAS1ADH5CYP2C19HAT1EP300
SCHEMBL22076963 0.89 TBXAS1 (0.49) TBXAS1ADH5CYP2C19PLA2G4A
SCHEMBL22078066 0.86 USP14 (0.49) TBXAS1HAT1EP300PLA2G10PLA2G4A
SCHEMBL22078067 0.86 TBXAS1 (0.47) TBXAS1PLA2G4AMAPTMAOB
SCHEMBL25492032 0.85 HAT1 (0.41) TBXAS1ADH5CYP2C19HAT1EP300
SCHEMBL20535801 0.85 ADH5 (0.49) ADH5CYP2C19HAT1EP300CYP3A4
SCHEMBL30772942 0.85 ADH5 (0.49) ADH5CYP2C19HAT1EP300CYP3A4
SCHEMBL30927852 0.85 ADH5 (0.49) ADH5CYP2C19HAT1EP300CYP3A4
SCHEMBL22078076 0.82 TBXAS1 (0.53) TBXAS1ADH5CYP2C19PLA2G4ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655244-B2 Carbazole compounds and methods of use thereof GSNO THERAPEUTICS, INC. (US) 2023-05-23 US disclosed
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSNO THERAPEUTICS, INC. 2020-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655244-B2 Carbazole compounds and methods of use thereof GSR, CBR3, CBR1 TBXAS1 1031/4885ADH5 93/4885CYP2C19 17/4885
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSR, CBR3, CBR1 TBXAS1 1031/4885ADH5 93/4885CYP2C19 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.